Composition of active agents to positively affect a robust mammalian endocannabinoid system tone to better address age related discomfort
AssigneeCompact Disc Incorporated
InventorRobert RAGER
Life of this patent
Estimating the term…
Abstract
Compositions and methods for prophylactically sustaining and/or maintaining a robust endocannabinoid system in patients for modulating excess inflammatory response and inflammatory diseases over the mammalian lifespan to mitigate age-related discomfort. Specifically, a method of treating inflammatory and neuropathic pain in a mammal by administering a synergistic pharmaceutical daily dosage form comprising: palmitoylethanolamide (PEA), beta-caryophyllene (BCP) and docosahexaenoic acid (DHA).
Claims19
A method of treating inflammatory and neuropathic pain in a mammal comprising:
- administering to a mammal in need thereof a synergistic pharmaceutical daily dosage form comprising:
- palmitoylethanolamide (PEA) in an ultramicronized form, beta-caryophyllene (BCP) and docosahexaenoic acid (DHA) in liquid form;
- wherein the palmitoylethanolamide (PEA), beta-caryophyllene (BCP) and docosahexaenoic acid (DHA) are contained in the daily dosage form in doses not exceeding about 1200 mg/day of the palmitoylethanolamide (PEA), not exceeding about 0.1 mL/kg of beta-caryophyllene (BCP), and not exceeding about 10 mg/kg of docosahexaenoic acid (DHA);
- wherein the pharmaceutical daily dosage form has palmitoylethanolamide in a weight percentage between about 1 and about 2%, beta-caryophyllene (BCP) in a weight percentage between about 10 and about 30% and docosahexaenoic acid (DHA) in a weight percentage between about 10 and about 30%.
A method of treating neuropathic and inflammatory pain in a mammal, comprising:
- administering to a mammal in need thereof a dosage form selected from the group consisting of a chew, tablet, capsule, or a liquid form of a synergistic pharmaceutical composition, wherein each dosage form of the pharmaceutical composition comprises:
- palmitoylethanolamide (PEA) in a weight percentage between about 1 and about 2%, beta-caryophyllene (BCP) in a weight percentage between about 10 and about 30% and docosahexaenoic acid (DHA) in a weight percentage between about 10 and about 30% and one or more compounds with anti-inflammatory activity in a total weight percentage ranging between 0 and about 20%.
Dependencies are inferred from the claim text.